Grace Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GRCE Nasdaq 2830 www.gracetx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Grace Therapeutics, Inc.

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 - Apr 14th, 2026 6:00 am
We're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate - Apr 4th, 2026 7:52 am
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences - Mar 19th, 2026 6:00 am
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - Feb 25th, 2026 6:00 am
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update - Feb 12th, 2026 6:00 am
Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference - Nov 17th, 2025 6:00 am
Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update - Nov 13th, 2025 6:00 am
Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting - Nov 11th, 2025 6:30 am
This Grace Therapeutics Insider Increased Their Holding By 12% Last Year - Nov 1st, 2025 8:14 am
Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review - Oct 23rd, 2025 6:00 am
We Think Grace Therapeutics (NASDAQ:GRCE) Needs To Drive Business Growth Carefully - Sep 23rd, 2025 7:55 am
Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting - Sep 22nd, 2025 6:00 am
Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 - Sep 18th, 2025 6:30 am
Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference - Sep 4th, 2025 6:00 am
Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 - Aug 27th, 2025 6:00 am
GRCE: Looking Ahead to Acceptance - Aug 13th, 2025 10:34 am
Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update - Aug 12th, 2025 6:00 am
GRCE: NDA Submitted - Jun 26th, 2025 3:30 am
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104 - Jun 25th, 2025 6:00 am
Grace Therapeutics, Inc. (NASDAQ:GRCE) Is Expected To Breakeven In The Near Future - Jun 24th, 2025 4:35 am